467 related articles for article (PubMed ID: 32398947)
21. Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer.
Amori G; Sugawara E; Shigematsu Y; Akiya M; Kunieda J; Yuasa T; Yamamoto S; Yonese J; Takeuchi K; Inamura K
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):767-774. PubMed ID: 33558663
[TBL] [Abstract][Full Text] [Related]
22. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
[TBL] [Abstract][Full Text] [Related]
23. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
24. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
[TBL] [Abstract][Full Text] [Related]
25. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
26. A promising target for breast cancer: B7-H3.
Jiang Y; Liu J; Chen L; Qian Z; Zhang Y
BMC Cancer; 2024 Feb; 24(1):182. PubMed ID: 38326735
[TBL] [Abstract][Full Text] [Related]
27. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
[No Abstract] [Full Text] [Related]
28. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
29. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres.
Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G
EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914
[TBL] [Abstract][Full Text] [Related]
30. B7-H3 in tumors: friend or foe for tumor immunity?
Li G; Quan Y; Che F; Wang L
Cancer Chemother Pharmacol; 2018 Feb; 81(2):245-253. PubMed ID: 29299639
[TBL] [Abstract][Full Text] [Related]
31. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
[TBL] [Abstract][Full Text] [Related]
33. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.
Benzon B; Zhao SG; Haffner MC; Takhar M; Erho N; Yousefi K; Hurley P; Bishop JL; Tosoian J; Ghabili K; Alshalalfa M; Glavaris S; Simons BW; Tran P; Davicioni E; Karnes RJ; Boudadi K; Antonarakis ES; Schaeffer EM; Drake CG; Feng F; Ross AE
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):28-35. PubMed ID: 27801901
[TBL] [Abstract][Full Text] [Related]
34. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
35. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors.
Nunes-Xavier CE; Karlsen KF; Tekle C; Pedersen C; Øyjord T; Hongisto V; Nesland JM; Tan M; Sahlberg KK; Fodstad Ø
Oncotarget; 2016 Feb; 7(6):6891-901. PubMed ID: 26771843
[TBL] [Abstract][Full Text] [Related]
36. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
37. Wharton's Jelly Mesenchymal Stromal Cells from Human Umbilical Cord: a Close-up on Immunomodulatory Molecules Featured In Situ and In Vitro.
Corsello T; Amico G; Corrao S; Anzalone R; Timoneri F; Lo Iacono M; Russo E; Spatola GF; Uzzo ML; Giuffrè M; Caprnda M; Kubatka P; Kruzliak P; Conaldi PG; La Rocca G
Stem Cell Rev Rep; 2019 Dec; 15(6):900-918. PubMed ID: 31741193
[TBL] [Abstract][Full Text] [Related]
38. Pediatric medulloblastoma express immune checkpoint B7-H3.
Li S; Poolen GC; van Vliet LC; Schipper JG; Broekhuizen R; Monnikhof M; Van Hecke W; Vermeulen JF; Bovenschen N
Clin Transl Oncol; 2022 Jun; 24(6):1204-1208. PubMed ID: 34988920
[TBL] [Abstract][Full Text] [Related]
39. An Fc-modified monoclonal antibody as novel treatment option for pancreatic cancer.
Lutz MS; Wang K; Jung G; Salih HR; Hagelstein I
Front Immunol; 2024; 15():1343929. PubMed ID: 38322253
[TBL] [Abstract][Full Text] [Related]
40. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
